Scientists explore varying immune responses in COVID-19 patients
A new study aims to further classify the immune response of COVID-19 patients with the goal of understanding the pathogenesis of the disease and accelerating the development of an effective vaccine to SARS-CoV-2 infection. The results of the study were published in Immunity on May 3.  Discuss
Athersys begins clinical trial for MultiStem cell therapy for COVID-19
Athersys announced that it has begun enrollment in its phase II/III study named MultiStem Administration for COVID-19 Induced Acute Respiratory Distress Syndrome.
Pfizer, BioNTech start clinical trials for mRNA COVID-19 vaccine
Clinical trials for a COVID-19 mRNA vaccine developed by Pfizer and BioNTech began on May 5 with New York University Grossman School of Medicine and the University of Maryland as the first centers to enroll patients in the U.S., said the companies.
Europe raises 7.4B euros for coronavirus response
On May 4, a group of nations and the European Commission raised 7.4 billion euros ($8 billion U.S.) to help make up for funding shortfalls in combating the COVID-19 outbreak. The funding will be used for a variety of purposes, including the development of diagnostics and vaccines.
Researchers investigate how a potent mAb blocks SARS-CoV-2
Based on previous research that explored therapies against SARS-CoV, a new report has identified a fully human monoclonal antibody (mAb) that prevents the SARS-CoV-2 virus from infecting cultured cells. Authored by a team of researchers from Utrecht University, Erasmus Medical Center, and Harbour BioMed, the report was published in Nature Communications on May 4.  Discuss
AbCellera secures COVID-19 drug development funding
AbCellera Biologics has secured $175.6 million Canadian ($124.7 million U.S.) from the Canadian government's Innovation, Science, and Economic Development Strategic Innovation Fund to advance its efforts to discover antibodies for use in antiviral COVID-19 drugs.
FDA issues EUA for remdesivir to treat severe COVID-19 cases
The U.S. Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for the investigational antiviral drug remdesivir to be used for the treatment of COVID-19. The EUA was issued to Gilead Sciences on Friday, May 1.
Cytokine storm may cause T-cell exhaustion in COVID-19 cases
Cytokine storms may impact the severity of COVID-19 cases by lowering T-cell populations, according to a study published in Frontiers in Immunology on May 1.  Discuss
U.K. schools get $3.8M to build COVID-19 vaccine, more
Citadel and Citadel Securities gifted 3 million pounds (about $3.8 million U.S.) to medical universities to accelerate COVID-19 research and vaccine development.
Inovio expands manufacturing for COVID-19 vaccine
Inovio has partnered with German contract manufacturer Richter-Helm BioLogics to produce large-scale quantities of Inovio's investigational DNA vaccine.
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter